Skip to main content

Advertisement

Table 1 2008 Prices for most-commonly used first-line ARV regimens

From: Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets

  Median (25th, 75th percentile) Regimen Prices* in USD
  Low
Income
Lower-Middle
Income
Upper-Middle
Income
Old First-Line Regimens from 2003 WHO Guidelines:    
3TC/NVP/d4T30 88 (83, 90) 87 (80, 151) 110 (84, 222)
EFV+3TC/d4T30 198 (183, 223) 147 (52, 253) 211 (172, 235)
3TC/NVP/ZDV** 154 (144, 162) 172 (154, 259) 161 (161, 189)
EFV+3TC/ZDV** 260 (246, 286) 216 (118, 298) 326 (260, 370)
New First-Line Regimens from 2006, 2009 WHO Guidelines:    
3TC+NVP+TDF** 244 (226, 278) 256 (244, 288) 387 (311, 591)
EFV+3TC+TDF** 349 (321, 399) 301 (207, 392) 477 (404, 527)
FTC/TDF+NVP** 361 (325, 366) 399 (292, 427) 525 (368, 726)
EFV+FTC/TDF** 465 (419, 487) 443 (256, 531) 616 (461, 663)
ABC+3TC+NVP 398 (361, 450) 418 (392, 457) 491 (443, 705)
ABC+EFV+3TC 503 (455, 571) 463 (355, 561) 581 (536, 641)
ABC+FTC+NVP n/a§ n/a§ n/a§
ABC+EFV+FTC n/a§ n/a§ n/a§
  1. *price/person/year calculated using the least expensive ARVs to create each regimen (see methods section)
  2. **first-line regimens recommended in 2009 WHO guidelines
  3. §price data unavailable; less than 5 purchases for at least one ARV in regimen